Objective:

To explore current trends and advancements in myopia management, focusing on treatment efficacy, emerging therapies, and the public health implications of myopia.

Key Findings:

• Pre-myopes are identified by a hyperopic reserve of less than +0.75D in North America, potentially higher in China, with significant implications for early intervention.
• Atropine treatments and low-level red light therapy show significant efficacy in delaying myopia onset, with specific percentages or metrics to illustrate effectiveness.
• Combination treatments and novel therapies like digital light devices are being explored for enhanced myopia management, highlighting the need for further research.

Interpretation:

The landscape of myopia management is evolving with evidence-based treatments that can significantly delay the onset and progression of myopia in children and adolescents, underscoring the urgency of addressing this public health issue.

Limitations:

• Potential rebound effects after treatment cessation remain unclear, necessitating further investigation.
• Long-term safety of new treatments and devices is still under investigation, with a need for comprehensive safety profiles.

Conclusion:

With numerous effective treatments available, ongoing research and clinical experiences will further enhance myopia management strategies, emphasizing the importance of continuous monitoring and adaptation.